| TOUT SUR LA RECHERCHE > Essais cliniques en cours |
| InVivo Therapeutics - Hydrogel / cellules souches neurales humaines |
| << < (15/19) > >> |
| Antho73420:
Thierry, au jour d'aujourd'hui, penses-tu qu'InVivo est le projet le plus avancé ? celui qui va aboutir en premier? |
| TDelrieu:
Merci Renaud ! Ton info vient compléter mon précédent post... :smiley: Autre news qui montre que la société InVivo Therapeutics est très active !!! --- Citer --- InVivo Therapeutics annonce l’expansion des brevets majeurs à d'autres affections du système nerveux Mercredi 8 juin 2011 CAMBRIDGE, MA - InVivo Therapeutics, une société axée sur le développement de technologies révolutionnaires pour le traitement des lésions de la moelle épinière, a annoncé aujourd'hui qu'elle a élargi le "champ d'utilisation" de sa licence, comportant des parties du système nerveux périphérique, le nerf caverneux entourant la prostate, le cerveau, la rétine et les nerfs crâniens. InVivo a une licence mondiale exclusive pour une vaste gamme de brevets, en co-propriété avec le Massachusetts Institute of Technology et le Harvard's Children's Hospital ("SMCC Licence"). La licence SMCC couvre déjà un large éventail de biopolymères pour traiter les lésions de la moelle épinière et promouvoir la survie et la prolifération des cellules dans la moelle épinière. La licence SMCC comprend 10 brevets émis aux États-Unis et 3 en attente de brevets aux Etats-Unis, ainsi que 67 brevets internationaux et 34 brevets internationaux en attente. InVivo mettra à profit son expérience dans la lésion de la moelle épinière afin de créer de nouvelles options thérapeutiques pour les lésions des nerfs périphériques, les injections épidurales, la réparation des nerfs caverneux après une chirurgie de la prostate, la réparation de la rétine, des tumeurs de la moelle épinière et pour des applications dans le cerveau. « C'est un moment excitant pour InVivo à quelques semaines de soumettre une Investigational Device Exemption (IDE) à la US Food and Drug Administration (FDA) pour notre premier produit. L'expansion des brevets permettra InVivo non seulement de développer des traitements avec de réels besoins médicaux, mais aussi d'ajouter des flux de revenus potentiels. Nous prévoyons que ces produits offriront de bonnes marges pour nos actionnaires avec des délais de développement relativement court. », a déclaré Frank Reynolds, PDG d'InVivo Therapeutics Cette suite de brevets est le résultat de décennies de recherches par le Dr. Robert S. Langer, au Massachusetts Institute of Technology (MIT), et ses équipes de recherche. «Nous sommes ravis d'appliquer ces découvertes dans de nouveaux domaines.", a dit Frank Reynolds. =========================== :arrow: TEXTE ORIGINAL EN ANGLAIS =========================== InVivo Therapeutics Announces Major Patent Expansion to Include Additional Nervous System Conditions Wednesday, 08 June 2011 CAMBRIDGE, MA--InVivo Therapeutics (OTCBB: NVIV), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced it has expanded the "Field of Use" of its existing patent license to include parts of the peripheral nervous system, the cavernous nerve surrounding the prostate, the brain, the retina and cranial nerves. InVivo has an exclusive, worldwide license to a broad suite of patents, co-owned by the Massachusetts Institute of Technology and Harvard's Children's Hospital (the "CMCC License"). The CMCC License previously covered a wide range of biopolymers to treat spinal cord injury and to promote the survival and proliferation of cells in the spinal cord. The CMCC License includes 10 issued U.S. patents and 3 pending U.S. patents as well as 67 international patents and 34 pending international patents. InVivo will leverage its experience in spinal cord injury to create new treatment options for peripheral nerve injuries, epidural injections, cavernous nerve repair following prostate surgery, retina repair, spinal cord tumors, and for applications in the brain. "InVivo has concurrently engineered our product portfolio resulting in low development costs, a vast knowledge of biomaterials, and a true platform technology that protects and supports nervous system tissue," said Frank Reynolds, CEO of InVivo Therapeutics. "This is an exciting time for InVivo's stakeholders as we are just weeks away from submitting an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) for our first product. The patent expansion will allow InVivo to not only develop treatments for unmet medical needs but also to add potential revenue streams. We expect these products to provide good margins for our shareholders with relatively short development timelines." This suite of patents is the result of decades of research by Dr. Robert S. Langer, the David H. Koch Institute Professor at the Massachusetts Institute of Technology, and his research teams at Langer Lab. Said Reynolds, "We are excited to apply these discoveries in new areas." For more information on this release, please visit http://nviv.irnewsroom.com/news-and-media Source : http://biomedreports.com/2011060868497/invivo-therapeutics-announces-major-patent-expansion-to-include-additional-nervous-system-conditions.html --- Fin de citation --- |
| Renaud:
InVivo Therapeutics et le Miami Project entament une nouvelle coloboration pour accélérer la recherche et peut être allier leurs technologies pour un nouveau traitement des lésions médullaires chroniques. Article en anglais si quelqu'un peut traduire: InVivo Therapeutics and The Miami Project to Cure Paralysis Form Strategic Research Collaboration to Develop Novel Treatments for Spinal Cord Injuries. CAMBRIDGE, Mass. – May 3, 2011 – InVivo Therapeutics (OTCBB: NVIV), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), and The University of Miami Miller School of Medicine’s Miami Project to Cure Paralysis, the world’s most comprehensive spinal cord injury research center, today announced a strategic research collaboration for the development of novel SCI treatments. The collaboration will evaluate InVivo’s biopolymer devices synergistically combined with cellular therapies, including The Miami Project’s Schwann cell technologies. Key components of the research collaboration agreement include: • in vitro and in vivo studies with combinations of biomaterials, Schwann cells and other cellular therapies and drugs • joint ownership of resulting intellectual property • right of first offer for InVivo to license and commercialize on a worldwide exclusive basis “This collaboration provides a tremendous opportunity for our technology platform”, said Frank Reynolds, CEO of InVivo Therapeutics. “To date, InVivo has been focused primarily on acute spinal cord injury research, and this partnership, which comes shortly before we file an Investigational Device Exemption for our first acute technology, will allow us to advance these technologies to the chronic spinal cord injury population with the Miami Project. The leadership of Nick and Marc Buoniconti has helped form what has become the world’s preeminent center of excellence for SCI research. We are honored to have them behind our efforts at InVivo and look forward to tapping their expertise to help us with our products,” said Frank Reynolds, CEO of InVivo Therapeutics”. InVivo’s biopolymer scaffoldings mimic the natural and protective properties of the extracellular matrix within the spinal cord to promote the proliferation and survival of implanted cells. In preclinical studies, InVivo’s biopolymer devices, alone, combined with drugs, or seeded with human neural stem cells, have demonstrated the remarkable ability to minimize scarring (astrogliosis) and promote post-SCI neural survival. “We are very pleased to form this partnership with InVivo Therapeutics and look forward to evaluating its innovative biopolymer scaffolding device,” said Marc Buoniconti, President of the Miami Project “We have been working on the problem of SCI for more than 25 years and look forward to exploring another promising avenue in our quest to address the enduring need for effective treatment options. The InVivo team shares our passion and personal commitment to finding new solutions to the challenges of spinal cord injury and paralysis.” Schwann cells are an integral component of The Miami Project’s research strategy because they are an important component of the peripheral nervous system. The cells are known to insulate (myelinate) and promote the growth and regeneration of nerve fibers. In preclinical models, Miami Project scientists have demonstrated locomotor function recovery, spared nerve function and nerve cell growth using autologous Schwann cell transplantation. The Miami Project has completed preclinical studies and plans to file an Investigational New Drug (IND) application for a Phase 1 human study using Schwann cells with the U.S. Food and Drug Administration in 2011. “InVivo’s biopolymer scaffoldings are novel tissue engineering solutions that may serve to improve functional recovery and promote the proliferation and survival of cellular therapies such as Schwann cells at the site of injury," said W. Dalton Dietrich, III, Ph.D., Scientific Director of The Miami Project. “We see significant potential in the natural synergies from combining these treatment approaches, both of which have been validated in preclinical studies. The Miami Project team looks forward to elucidating their potential and to working with InVivo toward our common goal of finding new and better treatments for spinal cord injury. |
| TDelrieu:
--- Citer --- InVivo et l’University of Miami font équipe sur la recherche des traumatismes médullaires 2 mai 2011 InVivo Therapeutics et l’University of Miami ont signé un accord de collaboration de recherche et de co-développement pour des traitements sur les lésions de la moelle épinière. La société fondée à Cambridge (Massachussetts) développe un polymère bio-compatible pour les traumatismes médullaires et prévoit de travailler avec le Miami Project to Cure Paralysis à l’university's Miller School of Medicine. En vertu de leur accord, InVivo et l’University of Miami prévoient de combiner la technologie du bio-polymère avec les cellules de Schwann et d'autres thérapies cellulaires. Une fonction des cellules de Schwann est de former des gaines de protection autour des neurones sensoriels et moteurs. Tout brevet obtenu en vertu de la collaboration de recherche sera détenue conjointement par l'université et InVivo. L’University of Miami a également convenu de donner à la société InVivo Therapeutics un droit pour une licence exclusive mondiale pour développer et commercialiser une technologie développée par le Miami Project. InVivo Therapeutics espère commencer une étude clinique avec son traitement à base de polymère dans la deuxième moitié de cette année. Le traitement d’InVivo utilise un polymère biodégradable conçu pour agir comme une « matrice extracellulaire de synthèse » et réduire la formation de cicatrices appelées astrogliose. La société a annoncé qu'elle allait présenter son polymère seul pour une autorisation de la FDA. En cours de route, elle pourrait demander des autorisations supplémentaires pour l'utilisation du polymère avec des médicaments anti-inflammatoires ou des composés à base de cellules souches. =========================== :arrow: TEXTE ORIGINAL EN ANGLAIS =========================== InVivo and University of Miami team up on spinal injury research May 2, 2011 by MassDevice staff InVivo Therapeutics Holdings Corp. and the University of Miami ink a research collaboration deal to for the co-development of spinal cord injury treatments. InVivo Therapeutics Holdings Corp. signed a research deal with the University of Miami for collaboration on spinal cord injury treatments. The Cambridge, Mass.-based company is developing a bio-compatible polymer scaffold for spinal injuries and plans to work with the Miami Project to Cure Paralysis at the university's Miller School of Medicine, according to a filing with the Securities & Exchange Commission. Under their agreement, InVivo and U. of Miami plan to combine the company's biopolymer technology with the university's Schwann cells and other cellular therapies, according to the filing. One function of Schwann cells is to form protective sheaths around motor and sensory neurons. Any intellectual property generated under the five-year research collaboration will be jointly owned by the university and InVivo, according the filing. U. Miami also agreed to give the company a right of first offer to an exclusive worldwide license to develop and further commercialize any technology developed by the Miami Project. InVivo, which went public in a reverse merger last October, is hoping to commence a clinical study on its polymer scaffold-based spine treatment during the second half of this year. The InVivo treatment uses a biodegradable polymer designed to act as a "synthetic extracellular matrix" and to reduce scar formation called astrogliosis. The company has said it will submit its scaffold device for FDA clearance alone. Down the road, it may apply for additional clearances for using the device with anti-inflammatory drugs or stem-cell-based compounds. Source : http://www.massdevice.com/news/invivo-and-university-miami-team-spinal-injury-research --- Fin de citation --- |
| TDelrieu:
On est très près d'une solution supplémentaire avec un polymère combiné à des cellules souches neurales. De plus, InVivo a déjà l'argent pour son essai clinique !!! Espérons que la FDA va donner son autorisation rapidement... :rolleyes: --- Citer ---6 décembre 2010 InVivo obtient une avance de 13 M $ pour le programme clinique sur les traumatismes médullaires La société est en attente de l'autorisation IDE de la FDA pour son polymère. In Vivo a récolté un total de 13 millions de dollars dans un placement privé. L'offre comprend 13 millions d'unités, chaque unité étant composée d'une action de InVivo et d'un bon donnant droit à l'acheteur d'acquérir une action au cours des cinq prochaines années à un prix de 1,40 $ par action. InVivo note que le placement de 10,5 millions d'unités initiales a été achevé en Octobre. InVivo est axée sur le développement de produits de réparation des lésions de la moelle épinière. L'entreprise met à profit son expertise pour développer des produits à base de polymères et d’échafaudages de polymères combinés à des cellules souches neurales humaines pour favoriser la réparation et la régénération. En Novembre, InVivo a inauguré sa première usine de fabrication et de développement à Medford, dans le Massachusetts. L'installation sera utilisée pour augmenter le processus de fabrication pour le polymère biocompatible d’InVivo qui sera utilisé pour traiter les plaies ouvertes des lésions graves de la moelle épinière. La société a déjà confirmé qu'elle est prête à commencer un essai clinique sur l'homme dès que sa demande à la FDA aura été accordée. =========================== :arrow: TEXTE ORIGINAL EN ANGLAIS =========================== Dec 6, 2010 InVivo Secures $13M In Advance of Clinical Program for Spinal Cord Injury Product Company is awaiting FDA clearance of IDE for polymer scaffold product. In Vivo raised a total of $13 million in a private placement that reached its maximum overallotment capacity. The offering comprised 13 million units, with each unit consisting of one share of InVivo common stock and one warrant entitling the purchaser to buy one share of common stock over the next five years at an exercise price of $1.40 per share. InVivo notes that placement of the initial 10.5 million units was completed in October. InVivo is focused on the development of spinal cord injury repair products. The firm is leveraging its expertise to develop both polymer-based products and polymer scaffolds combined with human neural stem cells to promote tissue repair and regeneration. In November InVivo established its first manufacturing and development facility in Medford, MA. The facility will be used to scale up the manufacturing process for InVivo's lead biocompatible polymer scaffolding device used to treat acute open-wound spinal cord injury. The firm has previously confirmed that it expects to start a human trial with the candidate once FDA clearance of the investigational device exemption application has been granted. Source : http://www.genengnews.com/gen-news-highlights/invivo-raises-13m-in-advance-of-proposed-clinical-program-for-spinal-cord-injury-product/81244338/ --- Fin de citation --- |
| Navigation |
| Index des messages |
| Page suivante |
| Page précédente |